Browse Category: Cancer Research

Eric Lefkofsky and Tempus Take on Cancer Research

What does Groupon and Date-Rich Cancer Treatment have in common? They are both the brainchild of one of tech’s biggest stars, Eric Lefkofsky. A recent article in Tech News Spy highlighted exactly what Lefkofsky has been up to since launching the startup Tempus. Tempus is a revolutionary company that is seeking to build the world’s largest library of human molecular and clinical data as well as construct a full external operating system that will make that data available to people working on cancer reserach or patient care.

Lefkofsky first began looking into cancer research after his wife was diagnosed with breast cancer. Known for his thirst for knowledge, Eric began to dig into cancer research and was dismayed to learn that there was a huge disconnect in the oncology field between the collection of actual data and how that data was being applied through digital technology. There was a huge amount of data being generated about cancer patients, their treatments and the outcomes but that information was not useful because there is no streamlined system in place that makes it accessible in an efficient manner.

After discovering this, Eric co-founded Tempus with the load of paving a new path to make data-enabled precision medicine the foremost tool used in cancer care. Tempus turned to technology to develop a platform that could analyze a cancer patient’s molecular and clinical data in a way that would produce effective information.

The final goal Tempus and Eric Lefkofsky have is to match help doctors match cancer patients with treatments that would work based on the data they have available and more information click here.

Eric Lefkofsky is probably best known as the co-founder of Groupon. However, he is also known in Chicago’s tech circles as a top influencer and mind. He has donated millions of dollars to cancer research before partially taking that research upon himself with the founding of Tempus and Eric’s lacrosse camp.

He is a graduate of the University of Michigan and also hold a law degree from the University of Michigan Law School. After graduating law school, he put his entrepreneurial mindset to work and became a power player in the dot-com world, forgoing the practice of law. He sits on the board of the Art Institute of Chicago and of Lurie’s Children’s Memorial Hospital in Chicago.

Oncotarget Publication Increasing the Impact of Science

Oncotarget is a traditional journal that is published every week. The journal covers the research made on all the oncology aspects. The journal has free access and is multidisciplinary. The publication is made online, and it can be printed if one made a special demand. Oncotarget aims at making the results of science widely available to the people. The journal also wants to use the insightful reviews they get to increase the impact the research has. It has tried to get rid of the borders the specialties have and to ensure that those special discoveries that are made are shared as fast as possible. The company has links to various biochemical science fields, and they use this to come up with the application of the clinical science to fight the illnesses.

Oncotarget was created in the year 2010. Impact Journals publishes the paper. The publication has two editors-in-chief. They are; Andrei Gudkov, Mikhail Blagosklonny. Andrei is from the Cancer Institute of Roswell Park. Since the issuance begun, it has published more than 350 papers that have topics related to oxygen. William Kaelin, Jr. and Gregg Semenza are also members of the team. They were awarded the Lasker Award because they discovered the pathway of sensing oxygen. Oncotarget also makes publication from the cancer research papers. The paper will also tend to make some articles on immunology, age-related diseases, Pharmacology, Mol Biology and cell, and pathology. This is because of the integrity of the human organism and the fact that tumor development is a complex issue.

Oncotarget helps researchers to contribute to the progress in the field of science. It does this by having leadership that is of prominent scientists. The paper aims at seeing individuals live without diseases. The success of the publication is what encouraged the paper to deal with other sections apart from oncology. The paper has a board that ensures the issues that are published are only the best ones. They play a major role in the success of journal. They are devoted and have had experience of several years.

Oncotarget goes ahead to allow authors from outside to submit any publications that they have on the related topics. The people who have an interest in writing issues on the same subject now have opportunities. However, they also work to ensure that the articles submitted are of high quality. To them, quality is everything. For this reason, all the writers who wish to submit what they write have to pass all their ethical tests to ensure it is of top quality.

To know more visit @: www.linkedin.com/in/mikhail-blagosklonny-91abb531/

Oncotarget’s Journal Shares Insightful and Accessible Medical Research Publications

Oncotarget is a peer-reviewed free access journal published weekly and covering various aspects of oncology research. It was started in 2010 and aims at making scientific results available while maximizing its impact through insightful reviews. The journal envisions a future where important discoveries are shared rapidly, and different biomedical fields are linked. The journal also hopes to enhance clinical and basic science in the fight against diseases.

Publications by Oncotarget Journal

On March 6th, 2017, Oncotarget published a journal in which Fabian V. Flipp, UC Merced professor, had mapped out melanoma’s genetic landscape and pinpointed a drug that was capable of battling the disease. In an interview, Mr. Flipp explained that the precision medicine sheds light on which drugs are effective to an individual’s unique epigenetic and genetic makeup. Mr. Flipp’s direction toward precision targeting proves that it is possible to control cancer through regulating epigenetic factors and hormone receptors at the same time. Oncotarget is also available on Dove Press.

A study by the University of Rochester Medical Center suggests that electronic cigarettes are as much harmful to teeth and gums as conventional cigarettes. The study led by Irfan Rahman, an Environmental Medicine professor at the UR School of Medicine and Dentistry, was published in Oncotarget. The study addresses the detrimental effects of e-cigarettes on oral health at a molecular and cellular level and is the first of its kind. Mr. Rahman explained that burnt vapors from e-cigarettes cause the release of inflammatory proteins which increase stress within cells causing damage that may result to oral diseases.

Watanabe-Smith is a postdoctoral fellow at the OHSU Knight Cancer Institute. Mr. Watanabe highlights that mutations are inclusive in our lives; he compares mutations to text message typos as they are mistakes found in a gene. However, he emphasizes that the major issue lies in which mutations are cancer causing and further asserts that the problem may pose a challenge if an efficient model system to test these mutations is not available. Mr. Watanabe’s research sought to understand one particular mutation in a leukemia test, which was published in the Oncotarget journal. While he was working on the model system, he encountered a new problem in which unexpected and additional gene mutation popped up every time he tried to sequence the patient’s DNA. That is why he decided to study this phenomenon.

Download output styles at Endnote.com